Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Date:2/28/2011

NEW YORK, Feb. 28, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following March 2011 investor conferences:Citigroup Global Health Care Conference (New York, NY)Wednesday, March 2, 201111:00am ETCowen & Company 31st Annual Health Care Conference (Boston, MA)Monday, March 7, 2011 4:45pm ETROTH 23rd Annual OC Growth Stock Conference  (Laguna Niguel, CA)Monday, March 14, 201112:00 Noon PTEach of the presentations will be live audio webcast, and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. Archived versions of each webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with approved therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

KERYX CONTACT:  Lauren Fischer  Director, Investor Relations  Keryx Biopharmaceuticals, Inc.  Tel: 212.531.5962
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... September 26, 2017 , ... Atmosera , a ... Management as a Service (RMaaS) to automate the deployment of websites and ... companies, e-tailers, and web development agencies who want to improve time-to-revenue with a ...
(Date:9/26/2017)... ... September 26, 2017 , ... CGL Electronic Security Inc., ... under its new umbrella, CGL Technologies, LLC. , The new CGL Technologies, LLC office ... Patitucci and Jon McCormack, both of whom have creative business development methods, who are ...
(Date:9/26/2017)... ... 26, 2017 , ... Two innovative companies are bringing to ... it is scientifically proven as well: ABAlife™. Euromed SA, a leading manufacturer of ... agreement with BioTherapeutics Inc. for patented technology for absiscic acid (ABA). , ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... As the ... news site, https://dealfeed.sutlr.com . People are constantly trying to find tips and stories ... industry, Sutlr deal feed brings you the top trending deals. The deals are organized ...
(Date:9/26/2017)... N.J. (PRWEB) , ... September 26, 2017 , ... ... at the shore, the John R. Elliott HERO Campaign for Designated Drivers proudly ... & Golf Club. , Thirty-one local bars and restaurants took on the challenge ...
Breaking Medicine News(10 mins):